Kodu・Aktsiate loetelu・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Avatud

SektorTervishoid

82.3 -0.87

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

81.96

Max

83.56

Põhinäitajad
By Trading Economics
Sissetulek	11M -156M
Müük	28M 222M
Aktsiakasum	-0.78
Kasumimarginaal	-70.082
Töötajad	999
EBITDA	-24M -137M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+30.89% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	28. okt 2026

Turustatistika
By TradingEconomics
Turukapital	-981M 16B
Eelmine avamishind	83.17
Eelmine sulgemishind	82.3

Uudiste sentiment

By Acuity

50%

171 / 340 Pingereas Healthcare

Bridgebio Pharma Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. aug 2026, 19:46 UTC

Correlated Moves

Shares lower amid broader biotechnology sector decline.

19. aug 2026, 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

18. aug 2026, 20:06 UTC

Social Media

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

14. aug 2026, 20:06 UTC

Social Media

News

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

13. aug 2026, 23:01 UTC

News

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

12. aug 2026, 19:51 UTC

News

Social Media

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

11. aug 2026, 22:36 UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

10. aug 2026, 23:21 UTC

News

Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

7. aug 2026, 20:03 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

6. aug 2026, 19:16 UTC

Social Media

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

5. aug 2026, 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

4. aug 2026, 19:36 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

3. aug 2026, 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

31. juuli 2026, 19:56 UTC

Correlated Moves

Social Media

BBIO shares decline, continuing a three-day trend amid sector weakness.

30. juuli 2026, 20:21 UTC

Correlated Moves

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

29. juuli 2026, 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

28. juuli 2026, 19:07 UTC

Correlated Moves

BBIO shares lower today amid declining biotech sector sentiment.

27. juuli 2026, 18:26 UTC

Social Media

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.

Võrdlus sarnastega

Hinnamuutus

Bridgebio Pharma Inc Prognoos

Hinnasiht

By TipRanks

30.89% tõus

12 kuu keskmine prognoos

Keskmine 108.56 USD 30.89%

Kõrge 157 USD

Madal 94 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Bridgebio Pharma Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

Osta

Hoia

Müü

Põhineb 17 analüütiku instrumendi Bridgebio Pharma Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

171 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.